KRAS and central nervous system cancer: 5‐Aza can also markedly reverse the aberrant level of miR‐200b,41 which may inhibit SUZ12 in cholangiocarcinoma.42 By removing the hypermethylation on the promoter regions of miR‐134,43 miR‐181c,44 and miR‐193b,45 5‐Aza can restrain KRAS expression in the glioma, gastric carcinogenesis, and esophageal adenocarcinoma, respectively.